Autoimmune disease

• 1. Introduction

  ›

  Autoimmune disease is not one condition but a family of more than 80 recognized disorders, each built on the same alarming mistake: the body's own immune system turns against healthy tissue it was designed to protect. That figure may already be an undercount. Recent scientific evidence suggests the true number of distinct conditions could exceed 100.

  Nearly any part of the body can be a target. The joints, the skin, the kidneys, the nervous system, the endocrine glands, the blood itself. A 2015 survey in the United States found that 98% of people with autoimmune diseases reported fatigue, and 89% called it a major issue. More than half described it as probably the most debilitating symptom they faced.

  Women make up roughly 80% of all autoimmune patients. Initial recognition of these diseases dates to the early 1900s. Well over a century later, no cure exists for the vast majority of them. What drives that misdirected immune attack, how doctors work to identify it, and what research is beginning to reveal about its underlying machinery are the threads this documentary follows.

• 2. A System Turned Inward

  ›

  The human immune system generates both T cells and B cells capable of reacting with the body's own proteins. In a healthy immune response, those self-reactive cells are either eliminated before activation, rendered inert through a process called anergy, or held in check by regulatory cells. When those safeguards fail, the immune system begins treating the body's own tissues as foreign invaders.

  This failure is the defining feature of autoimmune disease, and it sets the category apart from a closely related group called autoinflammatory diseases. Both can produce similar surface symptoms, including rash, swelling, and fatigue. The critical difference lies one level deeper. Autoinflammatory diseases involve a malfunction of the innate immune system, the body's older, more general-purpose defense mechanism. Autoimmune diseases involve a malfunction of the adaptive immune system, the more specialized, learned branch that should be capable of distinguishing self from non-self.

  One key checkpoint in that distinction is the thymus, an organ responsible for the maturation of T cells. Within the thymus, a process called negative selection eliminates T cells that react too strongly to the body's own molecules. If that mechanism is compromised, a pool of self-reactive cells can survive and become active within the immune system.

• 3. The Spectrum of Disease

  ›

  Coeliac disease targets the small intestine, where immune responses to gluten damage the villi, small fingerlike projections that enable nutrient absorption. The resulting inflammation raises the risk of gastrointestinal cancers and lymphoproliferative disorders. Removing gluten from the diet can partially or fully reduce that cancer risk.

  Graves' disease works through a different mechanism entirely. The body produces autoantibodies that attach to thyroid-stimulating hormone receptors, triggering unregulated release of thyroid hormone. The results include rapid heart rate, weight loss, nervousness, and irritability. Graves' disease also carries symptoms distinct from other thyroid conditions: bulging eyes and swelling of the lower legs.

  Multiple sclerosis directs the immune attack at myelin, the protective covering around nerve fibers in the central nervous system, which impairs communication between the brain and body. It carries an increased risk of central nervous system cancer, primarily in the brain. Rheumatoid arthritis, by contrast, attacks joints and is notably symmetrical, meaning both hands or both knees tend to be affected simultaneously. Despite being a joint disease, it also raises the risk of lung cancer, skin cancer, and hematologic cancers through the chronic inflammatory environment it creates.

  At the furthest end of the diagnostic spectrum sits undifferentiated connective tissue disease, a category for people whose test results and symptoms point toward connective tissue disease without meeting the criteria for any specific diagnosis. Between 30% and 40% of those patients eventually transition to a defined condition.

• 4. Genes, Environment, and Sex

  ›

  Twin studies have offered some of the clearest evidence for a genetic component. In multiple sclerosis, the concordance rate is 35% among identical twins compared to 6% among fraternal twins. Lupus and multiple sclerosis frequently appear across multiple members of the same family, and genome-wide association studies have identified specific genetic risk variants for diseases including type 1 diabetes and rheumatoid arthritis.

  The genetics of autoimmunity also reveal an evolutionary tension. Variants in the ERAP2 gene offer some resistance to infection while simultaneously raising the risk of autoimmunity, a trade-off that was positively selected over evolutionary time. In contrast, variants in the TYK2 gene protect against autoimmune diseases but increase susceptibility to infection. The historically high risk of dying from infection appears to have tipped the scales toward infection resistance, even at the cost of greater autoimmune risk.

  Environmental factors may account for up to 70% of autoimmune disease cases, according to current research. Among the implicated agents are chemicals including hydrazines, trichloroethylene, and tartrazines. Ultraviolet radiation has been linked to dermatomyositis. Pesticide exposure is associated with rheumatoid arthritis. Infection with SARS-CoV-2 has been linked in large-scale data analysis to a significantly increased risk of developing a wide range of new-onset autoimmune conditions.

  Women make up about 80% of autoimmune patients, and the explanation remains incomplete. Hormonal fluctuations appear relevant. Some diseases flare during pregnancy, when hormone levels are high, and improve after menopause. Puberty and pregnancy may both function as trigger events. The possibility that men are underdiagnosed because they interact less with the health system has also been raised as a contributing factor.

• 5. Mimicry and Mistaken Identity

  ›

  Campylobacter jejuni carries antigens that resemble, but are not identical to, molecules found in the human body. That resemblance can fool the immune system into producing antibodies that attack both the bacteria and the body's own tissue, a process known as molecular mimicry. Guillain-Barre syndrome illustrates the consequence: antibodies generated against a C. jejuni infection cross-react with the gangliosides in the myelin sheath of peripheral nerve axons.

  Streptococcus pyogenes, the bacterium responsible for strep throat, has been linked to rheumatic fever, which affects the heart. The Epstein-Barr virus, best known as the cause of mononucleosis, has been associated in some studies with subsequent development of both multiple sclerosis and lupus. These connections suggest that infections can act as catalysts, launching an immune response that the body cannot switch off once the original threat is cleared.

  The hygiene hypothesis offers a different angle on the same underlying problem. High levels of environmental cleanliness expose children to fewer antigens than was typical historically. One proposed consequence is an immune system that becomes overactive and more prone to misidentifying the body's own tissue as foreign, producing autoimmune or allergic conditions.

• 6. Diagnosis and the Challenge of Overlap

  ›

  Antinuclear antibody testing, commonly called ANA testing, is a standard tool in the diagnosis of systemic lupus erythematosus and several other autoimmune conditions. Blood counts, C-reactive protein measurements, and erythrocyte sedimentation rate tests can reveal patterns of inflammation. Thyroid function tests help identify autoimmune thyroid disorders. A biopsy of the small intestine can confirm coeliac disease by showing damage to the intestinal lining.

  Imaging adds another dimension. Chest X-rays and CT scans can identify lung involvement in rheumatoid arthritis or lupus. MRI can show inflammation or structural damage in the brain and spinal cord in multiple sclerosis.

  Despite this array of tools, diagnosis remains one of the harder aspects of autoimmune medicine. Symptoms are often fleeting, fluctuating between mild and severe, and a single patient may have more than one autoimmune condition simultaneously, a state called polyautoimmunity. A 2025 study drawing on electronic medical records from more than 15 million patients at six large academic medical systems in the United States found that over 34% of patients with one autoimmune disease had at least one additional autoimmune condition. By comparison, only 8.1% of cancer patients are diagnosed with a second primary malignancy. That co-occurrence rate points to shared underlying mechanisms that are still being mapped.

• 7. Treatment and What Lies Ahead

  ›

  Most autoimmune diseases are chronic with no definitive cure, so treatment is organized around control rather than elimination. Nonsteroidal anti-inflammatory drugs reduce inflammation. Glucocorticoids do the same. Disease-modifying anti-rheumatic drugs aim to limit tissue and organ damage from the inflammatory response. Intravenous immunoglobulin can be used to regulate immune activity. For diseases that cause specific deficiencies, such as type 1 diabetes or autoimmune thyroid conditions, replacement therapies supply what the body can no longer produce on its own.

  Because immunosuppressants blunt the overall immune response, every treatment carries the trade-off of reduced ability to fight infections. That tension shapes the practical management of these conditions over a lifetime.

  Newer approaches aim for greater precision. Monoclonal antibodies can block pro-inflammatory cytokines. Antigen-specific immunotherapy targets the abnormal cells driving the autoimmune response while leaving the rest of the immune system intact. Co-stimulatory blockade interrupts the pathway that activates the autoimmune attack. Regulatory T cell therapy harnesses a specific immune cell type to suppress that response. Stem cell transplantation has shown promising results in certain cases, and medical trials to replace the pancreatic beta cells destroyed in type 1 diabetes are ongoing.

  Thymoquinone, a compound found in the plant Nigella sativa, has been studied for its effects on inflammation and its potential in treating several autoimmune diseases. The first estimate of US prevalence for autoimmune diseases as a group was published in 1997 by Jacobson and colleagues, who calculated around 9 million affected individuals in a US population of 279 million. A 2012 update by Hayter and Cook extended the list to 81 diseases and put cumulative US prevalence at 5.0%, with rates of 3.0% for males and 7.1% for females.